Glomerulus-targeted protein nanoparticle pharmaceutical composition and application thereof

A nanoparticle and glomerulus technology, which is applied in the field of medicine, can solve the problems of cumbersome preparation process, in vivo toxicity, cumbersome and complicated methods, etc., and achieve the effect of simple and easy preparation technology, reducing toxic and side effects, and improving therapeutic effect

CN105944109AActive Publication Date: 2016-09-21SICHUAN UNIV
9 Cites 15 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2016-09-21

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a glomerulus-targeted protein nanoparticle pharmaceutical composition and an application thereof. The protein nanoparticle pharmaceutical composition is mainly prepared from a protein ingredient, a pharmacological active substance and a stabilizer, and the grain size of the protein nanoparticle pharmaceutical composition ranges from 10nm to 170nm. With the application of the pharmaceutical composition, passive targeted drug delivery of glomerular mesangial cells is achieved, and the aggregation concentration of a drug in a glomerulus is obviously improved or the aggregation duration of the drug in the glomerulus is prolonged, so that the curative effect of the drug is remarkably improved, and meanwhile, the toxic and side effects of the drug on a non-targeted part are greatly reduced.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a glomerulus-targeted protein nanoparticle pharmaceutical composition and a preparation method and application thereof, belonging to the technical field of medicine. Background technique

[0002] Glomerular diseases, including primary and secondary glomerulonephritis, are the main causes of chronic renal failure and end-stage renal disease, and are seriously threatening human health. According to statistics, in my country, glomerular diseases account for 54.4% of the causes of end-stage renal disease, of which glomerulonephritis accounts for 48.1%. Most glomerular diseases are immune-mediated inflammatory diseases. Therefore, immunomodulatory therapy is an important means for the treatment of immune-mediated glomerular inflammatory diseases. Currently, glucocorticoids and immunosuppressants are the main treatments in clinical practice. However, these two drugs have obvious side effects, such as femoral head necrosis and Cushin...

Examples

Embodiment 1

[0078] Preparation and characterization of human serum albumin nanoparticle tripterine composition and human serum albumin nanoparticle prednisolone composition by ultrasonic method

[0079] Dissolve tripterine 7mg or prednisolone 20mg and water-insoluble stabilizer soybean oil 50mg in 2mL dichloromethane:ethyl acetate (7:3, V / V), and then distill with 10mL human serum albumin Mix the aqueous solution (2%W / V), in an ice bath, ultrasonic power 500W (3s / 5s) for 8min, and then remove the organic mixed solvent by rotary evaporation under reduced pressure at 37°C to obtain human serum albumin nanoparticles tripterine composition and human serum albumin nanoparticle prednisolone composition. The particle size and potential were measured by a Malvern particle sizer, the morphology was characterized by a transmission electron microscope, and the encapsulation efficiency was determined by a Sephadex column method.

[0080] result:

[0081] As shown in Table 1, the prepared human seru...

Embodiment 2

[0085] Preparation of human serum albumin nanoparticle tripterine composition and human serum albumin nanoparticle prednisolone composition by high pressure homogenization method

[0086] Dissolve tripterine 7mg or prednisolone 20mg in 2mL dichloromethane:ethyl acetate (7:3, V / V), and then mix with 10mL human serum albumin (2%W / V) and water-soluble Solutol HS-15 40mg double-distilled aqueous solution was mixed, and the probe was ultrasonicated 15 times in an ice bath, and the obtained suspension was transferred to a high-pressure homogenizer, and the nanoemulsion was obtained by circulating and homogenizing 15 times in a pressure range of 15000Psi. Under reduced pressure at 37°C, the organic mixed solvent was removed by rotary evaporation to obtain the human serum albumin nanoparticle tripterine composition and the human serum albumin nanoparticle prednisolone composition, with an average particle size of about 100nm and a PDI Both are below 0.2.

Embodiment 3

[0088] Preparation of human serum albumin nanoparticle tripterine composition and human serum albumin nanoparticle prednisolone composition by microfluidic method

[0089] Dissolve tripterine 7mg or prednisolone 20mg and water-insoluble stabilizer medium-chain oil 50mg in 2mL dichloromethane:ethyl acetate (7:3, V / V), and then mix with 10mL human serum albumin (2 %W / V) and water-soluble stabilizer Solutol HS-15 40mg double-distilled aqueous solution mixed, the probe was ultrasonicated 15 times in an ice bath, the obtained suspension was transferred to a high-pressure homogenizer, and circulated within a pressure range of 20000Psi The nanoemulsion was obtained after 15 times of melting, and then the organic mixed solvent was removed by rotary evaporation under reduced pressure at 37°C, and the human serum albumin nanoparticle tripterine composition and the human serum albumin nanoparticle prednisolone composition were obtained. The average particle size is around 90nm, and the P...